Head and neck cancer drug
Intended for healthcare professionals

Cancer Nursing Practice

Clinical update Previous     Next

Head and neck cancer drug

Lynne Pearce Freelance health writer
Share to Facebook Share to X Share to Whatsapp Share to Email More...

Essential facts

Nivolumab is an immunotherapy drug and belongs to a group of drugs called monoclonal antibodies. It is used in the treatment of several cancers, including advanced melanoma, advanced non-small cell lung cancer and advanced renal cell carcinoma. It is also used in clinical trials for other types of cancer.

Cancer Nursing Practice. 16, 10, 11-11. doi: 10.7748/cnp.16.10.11.s9

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now

Are you a student? Our student subscription has content especially for you.
Find out more

Organisational access
Read this article via your institutional log in or pair token
Don’t have access via your organisation? Recommend to your librarian

07 December 2017 / Vol 16 issue 10

TABLE OF CONTENTS

DIGITAL EDITION

SUBSCRIBE

Journals